Inside the research
Penumbra, Inc.
PEN Research profile · latest available data
Price overview
$318.89
▼ -0.83 (-0.3%)
| 52w hi | $359.40 |
|---|---|
| 52w lo | $225.54 |
| Vol | 228.10K |
| As of | 25 Sep 2026 |
The Verdict
Our score -0.28
| Short | -0.31 |
|---|---|
| Medium | -0.22 |
| Long | -0.35 |
computed 2026-09-27
Key fundamentals
Penumbra, Inc.
Healthcare · Medical Devices
| Market cap | $12.56B |
|---|---|
| Enterprise value | $12.11B |
| Trailing P/E | 78.16x |
| Forward P/E | 52.00x |
| EV / EBITDA | 59.30x |
| P / S (ttm) | 8.35x |
| Profit margin | 10.7% |
| Return on equity | 11.4% |
| Revenue growth | +14.9% |
| Earnings growth | -23.5% |
| Debt / equity | 13.90 |
Layer Breakdown
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | +0.04 | |
| Sector | +0.08 | |
| Technical | -0.25 | |
| Earnings | +0.00 | |
| Sentiment | +0.00 |
macro × 1.00 · 2026-09-27
Business overview
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.
Risk Metrics
| Beta vs SPX | 0.55 |
|---|---|
| Corr SPX | 0.27 |
| Annual vol | 32.4% |
| Annual ret | +29.7% |
| Sharpe | 0.92 |
| Max DD | -25.8% |
Window: 504 trading days (504 obs)
Analyst Coverage
| Mean PT | $363.36 |
|---|---|
| High / Low | $374.00 / $326.00 |
| Median | $374.00 |
| Analysts | 14 |
| Strong Buy | 2 | |
|---|---|---|
| Buy | 2 | |
| Hold | 13 | |
| Sell | 0 | |
| Strong Sell | 0 |
Recent rating actions
| 2026-05-07 | Evercore ISI Group | → Outperform |
| 2026-05-07 | Citigroup | → Neutral |
| 2026-02-26 | Evercore ISI Group | → Outperform |
| 2026-01-20 | RBC Capital | → Sector Perform |
| 2026-01-20 | Canaccord Genuity | → Hold |
| 2026-01-16 | Truist Securities | → Hold |
Material Events
| Date | Event | 8-K |
|---|---|---|
| 2026-07-30 | Earnings Release, Exhibits | read |
| 2026-06-22 | Shareholder Vote | read |
| 2026-05-07 | Shareholder Vote | read |
| 2026-05-06 | Earnings Release, Exhibits | read |
| 2026-02-25 | Earnings Release, Exhibits | read |
| 2026-01-15 | Material Agreement, Earnings Release… | read |
| 2025-11-05 | Earnings Release, Exhibits | read |
| 2025-08-27 | Officer / Director Change, Reg FD Disclosure… | read |
| 2025-07-29 | Earnings Release, Exhibits | read |
| 2025-05-30 | Bylaws Amendment, Shareholder Vote… | read |
| 2025-04-23 | Earnings Release, Exhibits | read |
| 2025-02-21 | Officer / Director Change, Reg FD Disclosure… | read |
Insider Trades
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-19 | Elsesser Adam | CEO | Gift | 77.00K | — |
| 2026-04-02 | Grewal Harpreet | Sell | 100 | $32.82K | |
| 2026-03-15 | Narayan Shruthi | President | Withheld for tax | 117 | $39.33K |
| 2026-03-15 | Roberts Johanna | EVP, Gen. Counsel & Secre | Withheld for tax | 186 | $62.53K |
| 2026-03-15 | Yuen Maggie | Chief Financial Officer | Withheld for tax | 186 | $62.53K |
| 2026-03-15 | Shiu Lambert | Chief Accounting Officer | Withheld for tax | 150 | $50.43K |
| 2026-03-02 | Yuen Maggie | Chief Financial Officer | Sell | 2.43K | $832.47K |
| 2026-02-13 | Grewal Harpreet | Grant | 589 | — | |
| 2026-02-13 | Bose Arani | Grant | 589 | — | |
| 2026-02-13 | Leeds Janet | Grant | 589 | — |
Flow & Concentration
| Insider 180d net | -$32.82K |
|---|---|
| Insider buys / sells | 0 / 1 |
| Insider bias | Neutral |
| 13F holders | 9 |
| Top-5 share | 97.0% |
| HHI | 2,342 (moderate) |
Top Holders
| Holder | Value | Shares |
|---|---|---|
| State Street Corp | $392.56M | 1.24M |
| Millennium Management | $299.21M | 947.61K |
| Capital Research / Capital World | $222.23M | 703.82K |
| Citadel Advisors | $158.40M | 501.66K |
| Fidelity / FMR LLC | $66.62M | 211.00K |
| Renaissance Technologies | $25.10M | 79.50K |
| AQR Capital Management | $10.03M | 31.78K |
| Bridgewater Associates | $498.88K | 1.58K |
| T. Rowe Price Group | $14.09K | 44.62K |
As of 2026-06-30
SEC Filings
The Long Run
FY 2015–2025 · 11 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $1.06B | +42.1% | |
| Gross profit | $755.00M | +24.7% | |
| Operating income | $73.55M | +50.6% | |
| Net income | $177.69M | +61.6% | |
| Cash from ops | $97.33M | +38.2% |
Indices
Recent Sessions
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Sep 25 | $319.28 | $319.61 | $318.17 | $318.89 | 228.10K |
| Sep 24 | $318.98 | $320.27 | $318.33 | $319.72 | 483.00K |
| Sep 23 | $319.46 | $320.26 | $318.40 | $319.44 | 410.60K |
| Sep 22 | $319.80 | $319.80 | $318.49 | $319.39 | 797.90K |
| Sep 21 | $317.38 | $318.78 | $316.77 | $318.78 | 292.90K |
Understand the score. Research layers are inputs to a model, and the available data has limits.
Read the methodology →